1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–504.
2. Wang C, Yuan Y, Hunt RH. The Association Between Helicobacter pylori Infection and Early Gastric Cancer: A Meta-Analysis. Am J Gastroenterol 2007; 102: 1789–98.
3. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Schistosomes, liver flukes and Helicobacter pylori, Lyon, June 7–14, 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1–241.
4. Ekstrom AM, Held M, Hansson LE et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001; 121: 784–91.
5. Leodolter A, Naumann M, Malfertheiner P. Prevention of Gastric Cancer by Helicobacter pylori Eradication. Dig Dis 2004; 22: 313–9.
6. Correa P. Human gastric carcinogenesis: A multistep and multifactorial process. First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735–40.
7. Sipponen P, Marshall BJ. Gastritis and gastric cancer. Western countries. Gastroenterol Clin North Am 2000; 29: 579–92.
8. Huang JQ, Sridhar S, Chen Y, Hunt RH. Metaanalysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114: 1169–79.
9. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest 2007; 117: 60–9.
10. Genta RM. Helicobacter pylori, inflammation, mucosal damage, and apoptosis: pathogenesis and definition of gastric atrophy. Gastroenterology 1997; 113 (Suppl. 6): S51–S55.
11. Correa P. Chronic atrophic gastritis as a precursor of cancer. In: Precancerous lesions of the gastrointestinal tract. P.Sherlock, B.Morson, L.Barbara, and U.Veronesi, editors. Raven Press. New York, USA 1983; p. 145–53.
12. Halldorsdottir AM et al. Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. Dig Dis Sci 2003; 48: 431–41.
13. Li Q, Karam SM, Gordon JI. Diphtheria toxin-mediated ablation of parietal cells in the stomach of transgenic mice. J Biol Chem 1996; 271: 3671–6.
14. Van den Brink GR et al. Sonic hedgehog regulates gastric gland morphogenesis in man and mouse. Gastroenterology 2001; 121: 317–28.
15. Shiotani A et al. Evidence that loss of sonic hedgehog is an indicator of Helicobacter pyloriinduced atrophic gastritis progressing to gastric cancer. Am J Gastroenterol 2005; 100: 581–7.
16. Ramalho-Santos M, Melton DA, McMahon AP. Hedgehog signals regulate multiple aspects of gastrointestinal development. Development 2000; 127: 2763–72.
17. Nomura S et al. Alterations in gastric mucosal lineages induced by acute oxyntic atrophy in wild-type and gastrin-deficient mice. Am J Physiol Gastrointest Liver Physiol 2005; 288: G362–G375.
18. Price AB, Misiewicz JJ. Sydney classification for gastritis. Lancet 1991; 337: 174.
19. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol 2005; 36: 228–33.
20. Danesh J, Forman D, Collins R et al. Helicobacter pylori screening and gastric cancer. Lancet 1996; 348 (9029). 758–9.
21. Ito M, Haruma K. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: A 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002; 16 (8): 1449–56.
22. Rokkas T, Pistiolas D, Sechopoulos P et al. The Long-term Impact of Helicobacter pylori Eradication on Gastric Histology: a Systematic Review and Meta-analysis. Helicobacter 2007; 12 (Suppl. 2): 32–8.
23. Fuccio L, Zagari RM, Minardi ME, Bazzoli F. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007; 25: 133–41.
24. Kato M, Asaka M, Nakamura T et al. Helicobacter pylori eradication prevents the development of gastric cancer – results of a long-term retrospective study in Japan. Aliment Pharmacol Ther (symp ser 2) 2006; 203–6.
25. Tanaka A, Watari J, Tanabe H et al. Effect of eradication of Helicobacter pylori on genetic instabilities in gastric intestinal metaplasia. Aliment Pharmacol Ther (symp ser 2) 2006; p. 194–202.
26. De Vries AC, Kuipers EJ. Review article: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007; 26 (Suppl. 2): 25–35.
27. Uemura N, Mukai T, Okamoto S et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 639–42.
28. Malfertheiner P, Sipponen P, Naumann M et al. Helicobacter pylori Eradication Has the Potential to Prevent Gastric Cancer: A State-of-the-Art Critique. Am J Gastroenterol 2005; 100: 2100–15.
29. Lassen AT, Pedersen FM, Bytzer P et al. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: A randomised trial. Lancet 2000; 356: 455–60.
30. Chiba N, Veldhuyzen Van Zanten SJO, Escobedo S et al. Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori positive primary care patients with uninvestigated dyspepsia. Aliment Pharmacol Ther 2004; 19: 349–58.
31. Ebert M, Malfertheiner P. Pathogenesis of sporadic and familial gastric cancer – Implications for clinical management and cancer prevention. Aliment Pharmacol Ther 2002; 16 (6): 1059–66.
32. Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and heritable factors in the causation of cancer – Analyses of cohorts of twins from Sweden, Denmark and Finland. N Eng J Med 2000; 343 (2): 78–85.
33. Parsonnet J, Harris RA, Hack HM et al. Modeling cost effectiveness of H. pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996; 348: 150–4.
34. Malfertheiner Р, M_graud F, and O'Morain С et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56 (6): 772–81.
35. Kumar R, Tandon VR, Bano G et al. Comparative study of proton pump inhibitors for triple therapy in H. pylori eradication. Indian J Gastroenterol 2007; 26: 100–1.
36. Ohning GV, Walsh JH, Pisegna JR et al Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects. Aliment Pharmacol Ther 2003; 17 (9): 1109–14.
37. Pantoflickova D, Dorta G, Ravic M et al. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17 (12): 1507–14.
38. Dekkers CP, Beker JA, Thjodleifsson B et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer – a European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1998; 12 (8): 789–95.
39. Bruley des Varannes S, Gharib H, Bicheler V et al. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Aliment Pharmacol Ther 2004; 20 (8): 899–907.
40. Adachi K, Hashimoto T, Hamamoto N et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol 2003; 18 (12): 1392–8.
41. Take S, Mizuno M, Ishiki K et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005; 100: 1037–42.
42. Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Rev Anti Infect Ther 2005; 3 (6): 863–70.

В.Д.Пасечников, С.З.Чуков, О.А.Бакланова